Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 1.93
Ask: 2.11
Change: 0.12 (6.32%)
Spread: 0.18 (9.326%)
Open: 1.80
High: 2.10
Low: 1.80
Prev. Close: 1.90
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

Tue, 24th Nov 2020 21:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Gore Street Energy Storage Fund PLC - investor in utility-scale energy storage projects - Energises its 50 megawatt installed capacity Drumkee project in Northern Ireland. Drumkee becomes the largest energy storage project in Ireland. Expects its second 50 megawatt project, Mullavilly, to be energised in December. Both projects to be commissioned and operational in first quarter of 2021, taking portfolio's total installed capacity to 210 megawatts. "Notwithstanding the Covid lockdown and severe restrictions on movement, both project completion dates currently remain on schedule and budget."

----------

Martin Currie Global Portfolio Trust PLC - investment company focused on long-term returns in excess of the total return from the MSCI All Cos World index - Agrees draw down in full on unsecured three-year GBP30 million Royal Bank of Scotland International Ltd term loan with 1.181% fixed interest rate. Drawdown takes place on Tuesday. Loan represents around 10% of current net asset value.

----------

Immupharma PLC - London-based pharmaceutical company - Lind Global Macro Fund LP converts USD355,113 plus accrued unpaid interest of convertible security. This relates to convertible security deed from June 2020. Conversion price 11 pence per share, resulting in issue by Immupharma of 2.5 million shares.

----------

Helios Underwriting PLC - Lloyd's of London insurer - Receives valid acceptances for 252,843 open offer shares including applications under excess application facility. This represents 18% of open offer share available and raises GBP303,412. Non-Executive Chair Michael Cunningham and Non-Executive Director Andrew Christie subscribe for open offer entitlement of 6,053 and 2,392 open offer shares respectively.

----------

Block Energy PLC - exploration and production company focused on Georgia - Completes acquisition of Schlumberger Rustaveli Co Ltd and now holds licences for Georgian onshore blocks IX and XI. Company will now commence integration process and implement cost reduction plan. Has continues subsurface technical studies of Schlumberger Rustaveli assets "yielding economically attractive short and medium-term opportunities." Intends to apply for permits for workover and drilling programme across XI and West Rustavi licence areas.

----------

Uniphar PLC - healthcare services firm - Acquires RRD International, a US-based pharmaceutical advisory group that provides outsources consulting and execution services throughout early stages of product development. Purchase price includes upfront payment as well as contingent payment payable on achievement of earnings before interest, tax, depreciation, and amortisation-based targets. Acquisition expected to deliver return on capital employed in line with Uniphar's 12% to 15% target rate within three years. Further financial details not disclosed. Says: "acquisition will facilitate the growing requirement for Uniphar's delivery of US based expanded access programmes."

----------

Keras Resources PLC - mineral resource company - Notes that Chief Executive Russell Lamming has recently returned from Lome, Togo where he met with key government officials including Minister of Mines & Energy Mila Aziable and Minister of Investment Promotion Kayi Mivedor. Follow-up meetings also took place with state-owned Togo Invest Corp SA, which is helping assist with permitting process for the Nayega manganese mine in Northern Togo. Nayega is wholly owned by Kera's 85% owned Societe Generale de Mines subsidiary. Chief Executive Russell Lamming says: "Constructive meetings were undertaken with both the ministries of Mines and Energy and Investment Promotion during my recent trip to Togo; I expect to get feedback in the near term on what the pathway to final permitting at Nayega comprises."

----------

Lidco Group PLC - London-based hemodynamic monitoring company - As of Monday this week, Masimo has received valid acceptances in respect of 183.2 million Lidco shares, which it has acquired. These shares represent around a 75% stake in Lidco's existing issue share capital. Offer extended for 14 days and will stay open for acceptances until December 7. As announced November 2, Lidco has agreed to be acquired for GBP31.1 million, or 12 pence per share.

----------

FastForward Innovations Ltd - Guernsey-based closed-ended investment company - Notes update from hemp and CBD social commerce wellness company Yooma Corp, in which it holds a 10.65% stake. Yooma is launching clean CBD beauty brands MASK Skincare and Lab to Beauty ahead of the Black Friday and 12.12 China e-commerce events. These are being launched on BorderX Lab's China cross-border eCommerce app, Beyond. FastForward Chief Executive Ed McDermott: "We look forward to providing further updates regarding Yooma's commercial progress and its proposed merger with TSX quoted Globalive Technology Inc."

----------

Tern PLC - AIM-listed London-based investment firm specialising in internet of things - Portfolio company FVRVS Ltd secures GBP400,000 three-year contract with existing client. Client is an undisclosed "global pharmaceutical company". Contract to deliver recurring annual revenues over term from licences and support, enabling global rollout of the client's training solution using FundamentalVR's Fundamental Surgery virtual reality platform. Deal follows an initial GBP500,000 contract announced December 2019.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Net asset value per share loses 0.5% to 105.03 pence over four months ended October 31 while share price reflects 10% discount to NAV. Since month end, both NAV per share and share price up, with NAV per share on November 16 being 109.33p and share price totalling 105p, with discount narrowed to 4%. Paul ffolkes Davis, chair of investment adviser Rising Sun Management, says: "There have been a myriad of recent articles on the changing landscape in Japan for corporate activity and consolidation of smaller, cash-rich companies. Certainly our initial engagement with [Ebara Jitsugyo] suggests these companies are susceptible to focused shareholder intervention - the auguries for NAVF's ongoing campaign look bright."

----------

Armadale Capital PLC - investment company focused on natural resource projects in Africa - Picks Xinhai Mineral EPC, part of Chinese Yantai Xinhai group, to begin metallurgical bulk test work as part of the first phase of front-end engineering design studies for its Tanzanian Mahenge graphite project. Aim of work is to provide enough data to confirm result underpinning definitive feasibility study and confirm the preferred flow sheet before FEED completion. First bulk samples received by Xinhai.

----------

Urban Exposure PLC - residential development firm and asset manager - Plans shortly to proceed with tender offer for up to GP65 million in value of Urban Exposure shares at 75 pence per share. Completion of this tender offer is subject to shareholder approval. As previously disclosed, tangible net asset value as at June 30 was 77p per share with tender price representing a 2.6% discount to tangible NAV but a 7.9% premium to mid-market price of 69.50p per share at close of business on Monday. Company's current cash balance is GBP81 million.

----------

CATCo Reinsurance Opportunities Fund Ltd - Investor focused on offering returns from investments linked to catastrophe reinsurance risks - Has been advised of additional release of side pocked investment capital totalling around USD8 million. This is set to be paid to the company in January 2021, with CATCo planning to use the funds for a six compulsory redemption of shares. Updates breakdown of payments to ordinary shareholders is approximately USD2 million, with around USD6 million to C shareholders. Notes that subsequent to approval, and including sixth redemption, it will have returned around USD271.3 million to shareholders through compulsory redemptions, dividend, a tender offer and share buybacks.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2016 08:47

ImmuPharma completes patient recruitment in Lupuzor trial

(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor. The AIM-traded firm described Lupuzor as its lead programme for the p

Read more
16 Nov 2016 10:41

ImmuPharma Says Paper Detailing IPP-204106 Mechanism Published

Read more
14 Sep 2016 16:47

ImmuPharma makes positive progress in Lupuzor trials

(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday. The AIM-traded firm said it now had a total of 11 sites

Read more
14 Sep 2016 08:45

ImmuPharma Makes Progress With Lupuzor Phase III Trial

Read more
7 Jun 2016 06:59

ImmuPharma Begins Dosing Of European Patients In Lupuzor Trial

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
4 May 2016 09:17

ImmuPharma 2015 Loss Widens As It Focuses On Lupuzor Development

Read more
27 Apr 2016 15:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Mar 2016 10:27

ImmuPharma Begins Patient Recruitment In Europe For Lupuzor Trial

Read more
15 Feb 2016 15:32

ImmuPharma doses first patients in the US

(ShareCast News) - ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor. The AIM-traded drug discovery and development company confirmed in a statement that dosing had

Read more
15 Feb 2016 09:02

ImmuPharma Hopeful As US Patients Begin Dosing In Lupus Clinical Trial

Read more
5 Feb 2016 15:26

ImmuPharma to raise £7.5m for 'blockbuster' drug

(ShareCast News) - The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday. The AIM-traded specialist drug discovery and development company said the deal included a proposed conditional non-preemptive placing of no less than 11,824,877 Placing Shar

Read more
5 Feb 2016 10:32

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

Read more
5 Feb 2016 08:34

ImmuPharma Looks To Raise Minimum GBP7.5 Million In Equity (ALLISS)

Read more
7 Dec 2015 09:36

ImmuPharma Says US Sites Open For Lupuzor Phase III Trial Recruitment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.